The PREPARE II trial

Embedding a Pragmatic Trial Into Clinical Care During an Emergency Procedure.



Disclosures

Funding:

- None relevant to work discussed today
- Semler: NHLBI K23HL143053
- Russell: NHLBI 1 K08 HL148514

Disclosures or Potential Conflicts of Interest:

- None relevant to work discussed today
- Semler: Consultant to Baxter
- Russell: N/A

Overview

<u>For the Clinician</u>: Does an IV fluid bolus prevent severe hypotension during emergency intubation?



For the Researcher: How to embed an RCT into clinical care during an emergency procedure?

PREPARE II trial

Background

Rationale

Design

Results

Discussion

Background



Emergency Tracheal Intubation

- 2-5 million adults intubated in ED and ICU each year
- 75% of patients are comatose or delirious
- 5% of patients are in cardiac arrest
- Surrogates are frequently unavailable
- Median 5 min from decision-to-intubate to procedure

Choices between available treatments that clinicians must make for every emergency tracheal intubation for which the effect on patient outcomes is unknown

fluid bolus vs none

sedative-first vs NMB-first

NIV vs HFNC vs BMV

Bag-mask ventilation vs none during intubation

neuromuscular blocker vs none

etomidate vs ketamine

vasopressor vs none

ramped vs sniffing position

"apneic oxygenation" vs none

video vs direct laryngoscopy

hyperangulated vs standard geometry

Total number of RCTs of emergency tracheal intubation when we started training: 1

bougie vs stylet

Arbitrary Variation in Clinical Care



Arbitrary variation (different clinicians choosing different treatments for the same patient) = Clinical Equipoise

Structured Variation in a Clinical Trial



Rationale



Emergency Tracheal Intubation

2 minutes of very high risk for critically ill patients

Complications during tracheal intubation

Operating Room



2%

Intensive Care Unit



Russotto et al. JAMA, 2021

Cardiovascular collapse

- Composite of cardiovascular events during tracheal intubation
 - Systolic blood pressure < 65 mmHg
 - New or increased vasopressors
 - Cardiac arrest _____ between induction & 1 hour
 - Death
 J after intubation

Independently associated with in-hospital mortality

between induction & 2 minutes after intubation

Physiology of cardiovascular collapse during intubation

- 1) Decreased venous return due to increased intrathoracic pressure
- 2) Sedative-induced venodilation and arterial vasodilation
- 3) Decreased endogenous catecholamines



All potentially mitigated by a pre-intubation fluid bolus

Pre-intubation fluid bolus

- Intravenous infusion of 500 mL of crystalloid solution beginning prior to induction
- Observational studies: ~1/2 of patients receive a pre-intubation fluid bolus



Jaber et al. Intensive Care Med, 2010 Russotto et al. JAMA, 2021

International guidelines recommend a 500 mL fluid bolus before induction

BIA

British Journal of Anaesthesia, 120 (2): 323-352 (2018)

doi: 10.1016/j.bja.2017.10.021 Advance Access Publication Date: 26 November 2017 Respiration and the Airway

RESPIRATION AND THE AIRWAY

Guidelines for the management of tracheal intubation in critically ill adults

A. Higgs^{1,*}, B. A. McGrath², C. Goddard³, J. Rangasami⁴,
G. Suntharalingam⁵, R. Gale⁶, T. M. Cook⁷ and on behalf of Difficult Airway Society, Intensive Care Society, Faculty of Intensive Care Medicine, Royal College of Anaesthetists

Difficult Airway Society & Royal College of Anaesthetists

Guidelines 5 (AIDAA)

The All India Difficult Airway Association 2016 guidelines for tracheal intubation in the Intensive Care Unit

Address for correspondence: Prof. Jigeeshu Vasishtha Department of Anesthesiology, Critical Care and Pain, Tata Memorial Hospital, Dr. Ernest Borges Road, Parel, Mumbai - 400 012, Maharashtra, India E-mail: idivatia@vahoo.com Sheila Nainan Myatra, Syed Moied Ahmed¹, Pankaj Kundra², Rakesh Garg³, Venkateswaran Ramkumar⁴, Apeksh Patwa^{5,6}, Amit Shah^{5,6}, Ubaradka S Raveendra⁷, Sumalatha Radhakrishna Shetty⁷, Jeson Rajan Doctor, Dilip K Pawar⁸, Singaravelu Ramesh⁹, Sabyasachi Das¹⁰, Jigeeshu Vasishtha Divatia

Department of Anaesthesiology, articlal Care and Pain, Tata Memorial Hospital, Mumbai, Mahrashtra, ¹Department of Anaesthesiology and critical Care, J N Medical College and Hospital, AMU, Aligarh, ¹Utar Pradesh, ²Department of Anaesthesiology and Critical Care, JIPMER, Puduchery, ³Department of Onco-Anaesthesiology and Palliative Medicine, Dr. BRAIRCH, All India Institute of Medical Sciences, ¹Department of Anaesthesia, All India Institute of Medical Sciences, New Delhi, ¹Oepartment of Anaesthesiology, Kasturba Medical College, Manipal, ¹Department of Anaesthesiology and Critical Care, K S Hegde Medical Academy, Nitte University, Mangalore, Karnataka, ⁴Kailash Cancer Hospital and Researci Centre, ¹Department of Anaesthesia, Vadodara Institute of Neurological Sciences, Vadodara, Gujarat, ¹Pepartment of Anaesthesia, Kanchi Kamakoti College Dartment, Chengal, India ¹Anaesthesiology, North Bengal Medical College, Darteling, West Bengal, India

The All India Difficult Airway Association

Higgs et al. Br J Anaest, 2018 Myatra et al. Indian J Aneasth, 2016

Prior data on a pre-intubation fluid bolus

Effect of a fluid bolus on cardiovascular collapse among critically ill adults undergoing tracheal intubation (PrePARE): a randomised controlled trial

David R Janz, Jonathan D Casey, Matthew W Semler, Derek W Russell, James Dargin, Derek J Vonderhaar, Kevin M Dischert, Jason R West, Susan Stempek, Joanne Wozniak, Nicholas Caputo, Brent E Heideman, Aline N Zouk, Swati Gulati, William S Stigler, Itay Bentov, Aaron M Joffe, Todd W Rice, for the PrePARE Investigators* and the Pragmatic Critical Care Research Group

The PrePARE Trial

- **Design:** RCT in 9 U.S. ICUs
- **Population:** ICU patients undergoing intubation
- Intervention: Initiation of a 500 mL crystalloid fluid bolus before induction
- Outcome: Cardiovascular collapse
- **Result:** Stopped for futility at interim after enrolling 337 patients



Rationale for PREPARE II

	Number of individuals		Number of events			Relative risk (95% CI)	p value for interaction		
	Fluid bolus	No fluid bolus	Fluid bolus	No fluid bolu	IS				
Septic shock	39	33	13 (33%)	12 (36%)			0·91 (0·48–1·72)	0.67	
No septic shock	129	136	20 (16%)	19 (14%)		•	1.10 (0.62–1.98)	0.07	
On vasopressors	28	28	11 (39%)	12 (43%)	•		0.91 (0.48–1.71)	0.60	
Not on vasopressors	140	141	22 (16%)	19 (14%)		•	1.16 (0.66–2.05)	0.00	
NIV preox	39	30	8 (21%)	12 (40%)		-	0.51 (0.24–1.09)	0.022	
No NIV preox	129	139	25 (19%)	19 (14%)	_	• • · · ·	1.41 (0.82–2.44)	0.032	
BMV	81	84	13 (16%)	22 (26%)		-	0.61 (0.33–1.13)	0.0080	
No BMV	87	85	20 (23%)	9 (11%)		●	2.17 (1.04–4.49)	0.0080	
Overall	168	169	33 (20%)	31 (18%)		-	1.07 (0.68–1.66)		
						·0 10			
					Favours fluid bolus	Favours no fluid bolus			
					Relative risk of card with fluid bo	diovascular collapse olus (95% CI)			

Rationale for PREPARE II

ORIGINAL ARTICLE

Bag-Mask Ventilation during Tracheal Intubation of Critically Ill Adults

Jonathan D. Casey, M.D., David R. Janz, M.D., Derek W. Russell, M.D., Derek J. Vonderhaar, M.D., Aaron M. Joffe, D.O., Kevin M. Dischert, M.D., Ryan M. Brown, M.D., Aline N. Zouk, M.D., Swati Gulati, M.B., B.S., Brent E. Heideman, M.D., Michael G. Lester, M.D., Alexandra H. Toporek, M.D., <u>et al.</u>, for the PreVent Investigators and the Pragmatic Critical Care Research Group*



Oxygen Saturation

PREPARE II Research Question

Does the intravenous infusion of a 500 mL crystalloid fluid bolus beginning prior to induction of anesthesia decrease the incidence of cardiovascular collapse for critically ill adults undergoing tracheal intubation with positive pressure ventilation?



Does an IV fluid bolus prevent severe hypotension during emergency intubation?

PREPARE II Research Methods Question

- Time-to-intervention < 5 minutes
- No research personnel generally present



How to design and conduct an RCT of fluid bolus during emergency intubation?

Design

PREPAREII Trial Design

- **Design:** Multicenter, parallel-group, randomized trial comparing fluid bolus vs none among critically ill adults receiving positive pressure ventilation during intubation
- Sites: 11 academic ICU sites across the United States
- Inclusion Criteria:
 - Adult undergoing tracheal intubation with sedation
 - Positive pressure ventilation between induction and laryngoscopy is planned

• Exclusion Criteria:

- Pregnant or prisoner
- Intubation too emergent to perform study procedures
- Clinicians determined that fluid bolus is either required or contraindicated



Simple eligibility criteria: can be judged by clinicians even during an emergency.

Waiver of Informed Consent

Minimal risk

- Both treatments (fluid bolus and none) are commonly given to patients in clinical care
- Both are interventions to which the patient would likely be exposed even if not participating in a study
- No definitive prior data suggested clinical outcomes were better with one approach relative to another
- Both treatments are consistent with optimal care for that individual patient from the perspective of the treating clinician (otherwise patient is excluded)

Impracticability of obtaining informed consent prior to emergency intervention

- 75% of patients in coma or delirious; surrogates frequent absent
- 5 minutes from clinical decision to intubate until start of procedure; no study personnel present

Information for patients and families

• Participants were provided an IRB-approved informational document describing the research and their participation, and providing contact information for investigators for future questions or concerns

Randomization and Blinding

- Allocation concealed until randomization
- 1:1 randomization in blocks of 2, 4, & 6, stratified by site
- Not blinded after randomization



BEFORE opening envelope, you must read criteria **OUT LOUD** and confirm eligibility in study: 1. Patient not a **prisoner**, **pregnant**, or **child** (<18 yrs)

- 2. Positive pressure (bipap or bag-mask) will be provided between induction and intubation
- 3. Sedation will be given before intubation

Opening this envelope ENROLLS the patient. By opening the envelope, you are confirming this patient is eligible for the study.





Envelopes with randomized group assignment kept with intubation equipment

Interventions





Group assignment sheet with succinct instructions to be implemented by clinical personnel

Data Collection

- 1-page data collection sheet
- Site-specific observers
- Rapid feedback from research team on data quality

Box 1: Data to be entered by OBSERVER
1. BEFORE MEDS PUSHED
NEW fluid bolus started prior to meds pushed: Yes / No
Vasopressor bolus or dose increase prior to meds pushed: Yes / No
2. AS INTUBATION MEDS PUSHED
Time first med pushed::(hr/min/sec)
O2 Sat as meds pushed:%
SBP as meds pushed: mmHg
2. TIME laryngoscope blade first entered mouth:::(hr/min/sec)
3. TIME ET tube successfully placed in airway::(hr/min/sec)
4. AFTER MEDS PUSHED until 2 MIN AFTER TUBE PLACED IN AIRWAY
Lowest O2 Sat: %
Lowest SBP: mmHg
NEW Fluid bolus started after meds pushed: Yes / No
New or increased vasopressor: None / Neostick / Levophed / Epi / Other
Box 2: Data to be entered by Intubator Patient MRN:
Box 2: Data to be entered by Intubator Patient MRN:
Box 2: Data to be entered by Intubator Patient MRN:
Box 2: Data to be entered by Intubator Patient MRN: 1. Estimated # of times you've intubated previously: 2. Bag-valve-mask ventilation (bag squeezed) starting at induction: Yes / No 3. Bag-valve-mask ventilation (bag squeezed) at any point between induction and intubation: Yes* / No
Box 2: Data to be entered by Intubator Patient MRN: 1. Estimated # of times you've intubated previously:
Box 2: Data to be entered by Intubator Patient MRN: 1. Estimated # of times you've intubated previously:
Box 2: Data to be entered by Intubator Patient MRN: 1. Estimated # of times you've intubated previously:
Box 2: Data to be entered by Intubator Patient MRN:
Box 2: Data to be entered by Intubator Patient MRN: 1. Estimated # of times you've intubated previously:
Box 2: Data to be entered by Intubator Patient MRN:
 Box 2: Data to be entered by Intubator Patient MRN:
 Box 2: Data to be entered by Intubator Patient MRN:
Box 2: Data to be entered by Intubator Patient MRN:
 Box 2: Data to be entered by Intubator Patient MRN:
Box 2: Data to be entered by Intubator Patient MRN:
Box 2: Data to be entered by Intubator Patient MRN:



Clinical data captured into source document in real-time by clinical personnel

Primary Outcome

Cardiovascular collapse

- Systolic blood pressure < 65 mmHg]
- New or increased vasopressors
- Cardiac arrest
- Death

between induction & 1 hour after intubation

between induction & 2 minutes after intubation

Sample Size

- Initial Sample Size (n=750)
 - Power = 80%
 - Alpha = 0.05
 - Incidence of primary outcome in control group = 25%
 - Absolute difference detectable = 8.75% (35% relative risk difference)
 - Missing data = 5%
- Final Sample Size (**n=1065**)
 - Pre-specified sample size re-estimation by DSMB at interim analysis to maintain 80% power to detect 35% relative risk difference using observed event rate in control group
 - Increased sample size by 315 patients (42%)

Statistical Analyses of Primary Outcome

Intention-to-Treat

• Only patients withdrawn from the trial were 2 discovered to be prisoners

Primary Analysis

• Absolute risk difference between two treatment arms (Chi-square)

Results

Trial Dates

Enrollment start: Pause during COVID: Enrollment end: Follow up complete: 1 February 2019
 March 2020 to August 2020
 24 May 2021
 21 June 2021







Patient Characteristics	Flui (N	d Bolus = 538)	No Fluid Bolus (N= 527)	
Age (years)	61	(51-70)	62	(51-71)
Female sex	220	(40.9)	228	(43.3)
Body mass index, kg/m ²	28	(24-33)	28	(24-33)
Indication for intubation				
Acute respiratory failure	320	(59.5)	324	(61.5)
Altered mental status	110	(20.4)	106	(20.1)
Other	108	(20.1)	97	(18.4)
APACHE II score	20	(14-25)	18	(14-25)
Vasopressors 1 hour prior	107	(20.0)	102	(19.4)
Sepsis or septic shock	312	(58.0)	318	(60.3)
Etomidate as induction	413	(76.8)	416	(78.9)
Ketamine as induction		(12.3)	55	(10.4)

Data given as no. (%) or median [IQR]

Receipt of a Fluid Bolus

	Fluid Bolus (N= 538)		No Fluid Bolus (N= 527)	
Fluid bolus	535	(99.4)	6	(1.1)
No fluid bolus	3	(0.6)	521	(98.9)

Receipt of a Fluid Bolus

		Fluid Bolus (N= 538)		No Fluid Bolus (N= 527)	
Fluid bolus	535	(99.4)	6	(1.1)	
No fluid bolus	3	(0.6)	521	(98.9)	
Volume of intravenous fluid from enrollment to 2 minutes after intubation, mL	500	(300-500)	0	(0-0)	



99% compliance with group assignment during an emergency procedure

Primary Outcome

	Fluid Bolus (N= 538)	No Fluid Bolus (N= 527)	Absolute risk difference (95% Cl)	P value
Primary outcome: Cardiovascular collapse				



Effect Modification



Exploratory Clinical Outcomes	Fluid Bolus (N= 538)		No Fluid Bolus (N= 527)		Absolute difference (95% Cl)	
Secondary Outcome						
In-hospital mortality	218	(40.5)	223	(42.3)	-1.8% (-7.9% to 4.3%)	
Exploratory clinical outcomes						
Ventilator-free days	14	(0-25)	12	(0-2)	2.0 (-10 to 15)	
ICU-free days	9	(0-22)	9	(0-22)	-0.5 (-9.0 to 9.5)	
Lowest SBP, mmHg	116	(93-139)	113	(95-134)	3 (-3.0 to 7.0)	
Change in SBP, mmHg	-7	(-26-0)	-9	(-27-0)	2.0 (-2.0 to 5.0)	

Data given as no. (%) or median [IQR]

Discussion

PREPAREII Summary

• 1,065-patient trial with 99% protocol compliance

• Administration of a fluid bolus during emergency tracheal intubation did not prevent cardiovascular collapse (21.0% vs 18.2%)

 No significant difference in in-hospital mortality (40.5% vs. 42.3%)

Strengths

- Conduct at multiple centers
- Severely-ill population (mortality 40%)
- Collection of trial endpoints by an independent observer
- High protocol compliance
- No missing data for primary outcome

Limitations

- Cardiovascular collapse is a surrogate outcome that may not be meaningful to patients
- Does not inform the effectiveness of fluid administration for other indications ("rescue fluids")



So, why DIDN'T a fluid bolus work?

The right Patient Population?

- Did the trial enroll patients likely to benefit from fluid bolus administration?
 - PREPAREII used predictive enrichment to target patients most likely to benefit
 - No evidence of benefit from fluid bolus overall or in any subgroup
- Did the trial exclude patients for whom clinicians felt fluid would be beneficial?
 - Only 27 patients (1.7% of the screened population) were excluded from PREPAREII because a fluid bolus was felt by clinicians to be requisite
- Did the trial enroll patients likely to experience the outcome?
 - High event rate: cardiovascular collapse in 20% (and 40% mortality)
 - No evidence of benefit from fluid bolus in patients at high or low risk of the outcome

Was the assigned intervention delivered? (Did adequate separation between groups occur?)

- Intervention (500cc fluid bolus)
 - Same as in prior studies
 - Same as in guidelines
- Median fluid volume given
 - 500 mL in fluid bolus group
 - 0 mL no fluid bolus group



Was the <u>sample size</u> too small?

Sample size increased from 750 to 1,065 to ensure adequate power

Effect estimate favored the no fluid bolus group

• No suggestion of benefit in any subgroup

• No suggestion of benefit in any secondary analysis

PrePARE

Effect of a fluid bolus on cardiovascular collapse among critically ill adults undergoing tracheal intubation (PrePARE): a randomised controlled trial

David R Janz, Jonathan D Casey, Matthew W Semler, Derek W Russell, James Dargin, Derek J Vonderhaar, Kevin M Dischert, Jason R West, Susan Stempek, Joanne Wozniak, Nicholas Caputo, Brent E Heideman, Aline N Zouk, Swati Gulati, William S Stigler, Itay Bentov, Aaron M Joffe, Todd W Rice, for the PrePARE Investigators^{*} and the Pragmatic Critical Care Research Group



PrePARE II

Effect of Fluid Bolus Administration on Cardiovascular Collapse Among Critically III Patients Undergoing Tracheal Intubation A Randomized Clinical Trial

Derek W. Russell, MD; Jonathan D. Casey, MD, MSc; Kevin W. Gibbs, MD; Shekhar Ghamande, MD; James M. Dargin, MD; Derek J. Vonderhaar, MD; Aaron M. Joffe, DO; Akram Khan, MD; Matthew E. Prekker, MD, MPH; Joseph M. Brewer, DO; Simanta Dutta, MD; Janna S. Landsperger, MS, ACNP-BC; Heath D. White, DO, MS; Sarah W. Robison, MD; Joanne M. Wozniak, MS, PA-C; Susan Stempek, MMSc, PA-C; Christopher R. Barnes, MD; Olivia F. Krol, BS; Alejandro C. Arroliga, MD, MS; Tasnim Lat, DO; Sheetal Gandotra, MD; Swati Gulati, MBBS, MS; Itay Bentov, MD, PhD; Andrew M. Walters, MD; Kevin M. Dischert, MD; Stephanie Nonas, MD; Brian E. Driver, MD; Li Wang, MS; Christopher J. Lindsell, PhD; Wesley H. Self, MD, MPH; Todd W. Rice, MD, MSc; David R. Janz, MD, MSc; Matthew W. Semler, MD, MSc; for the PREPARE II Investigators and the Pragmatic Critical Care Research Group



Conclusion

JAMA

QUESTION In critically ill adult patients undergoing tracheal intubation, does intravenous infusion of a crystalloid solution as a 500-mL fluid bolus decrease the incidence of severely low blood pressure, cardiac arrest, or death during or shortly after the procedure?

CONCLUSION Among critically ill adults undergoing tracheal intubation, administration of a fluid bolus did not significantly decrease the incidence of cardiovascular collapse.



Among critically ill adults undergoing tracheal intubation, administration of a fluid bolus does not prevent cardiovascular collapse.

Takeaways for the Researcher

• The Imperative

- In clinical care, patients are receiving treatments that are ineffective (or harmful).
- Without RCTs, we cannot know which treatments are helpful and which are not.
- Emergency research has largely focused on a small number of conditions (e.g., cardiac arrest, stroke) and neglected many common treatments (e.g., intubation).
- We must establish the regulatory and logistical methods needed to examine in RCTs the full range of emergency treatments patients are receiving in clinical care.

Embedding RCT procedures within emergency care can:

- Deliver treatments in the manner that they are delivered in clinical care.
- Collect the data on which clinicians and patients base decisions.
- Enroll diverse and representative trial populations (to understand H.T.E.).



How can we improve acute and emergency care through more broadly embedding RCTs into clinical care?

Thank you!

Derek W. Russell, MD*; Jonathan D. Casey*, MD, MSc; Kevin W. Gibbs, MD; Shekhar Ghamande, MD; James M. Dargin, MD; Derek J. Vonderhaar, MD; Aaron M. Joffe, DO; Akram Khan, MD; Matthew E. Prekker, MD, MPH; Joseph M. Brewer, DO; Simanta Dutta, MD; Janna S. Landsperger, MS, ACNP-BC; Heath D. White, DO, MS; Sarah W. Robison, MD; Joanne M. Wozniak, MS, PA-C; Susan Stempek, MMSc, PA-C, Christopher R. Barnes, MD; Olivia F. Krol, BS; Alejandro C. Arroliga, MD, MS; Tasnim Lat, DO; Sheetal Gandotra, MD; Swati Gulati, MBBS, MS; Itay Bentov, MD, PhD; Andrew M. Walters, MD; Kevin M. Dischert, MD; Stephanie Nonas, MD; Brian E. Driver, MD; Li Wang, MS; Christopher J. Lindsell PhD; Wesley H. Self, MD, MPH; Todd W. Rice, MD, MSc; David R. Janz, MD, MSc; Matthew W. Semler, MD, MSc

Stephen P. Peters MD. PhD: Muhammad Ali, MBBS: Rita N. Bakhru, MD. MS: Scott Bauer, ANP-BC: Christina R. Bellinger, MD: Amanda M. Brown, PA-C: Blair Brown, MD: Jerri Brown, ADN, RN; Caitlin Bumgarner, ACGNP; Wendy Butcher, RN, BSN; Megan Caudle, ACGNP; Arjun B. Chatterjee, MD; David J. Chodos, MD; Gerardo Corcino, RN, BSN; Nathan S. Cutler, MD; Travis L. Dotson, MD; Daniel C. Files, MD; Jonathan L Forbes, DO; John P. Gaillard, MD; Katherine A. Gershner, DO; Shannon Ginty, PA-C; Kiadrick R. Hood, RN, MSN, CMSRN; April Hazelwood, ADN, RN; Katherine Hendricks, FNP; Kelly Jacobus, PA-C; Jonathan T. Jaffe, MD; Stacy Kav. ACGNP; Chad A. Kloefkorn, MD; Jennifer Krall, MD; Margo T. Lannan, MD; Cornelia Lane, ACGNP; Cynthia Lanning, BSN, RN; Jessica Lyons, PA-C; William I. Mariencheck Jr., MD; Chad R. Marion, DO, PhD: Matthew A, Maslonka, MD: Sara McClintock, ACGNP: Nathaniel M, Meier, MD: Matthew C, Miles, MD, MEd: Peter J, Miller, MD: Sophia Mitchell, PA-C: Wendy C. Moore, MD; Katherine Moss, PA-C; Andrew M. Namen, MD; Dustin L. Norton, MD; Stella B. Ogake, MD; Jill A. Ohar, MD; Victor E. Ortega, MD, PhD; Jessica A. Palakshappa, MD, MS; Rodolfo M. Pascual, MD; Sandi Pascual, ANP-BC; Aaron Pickens, MD; Himanshu Rawal, MBBS; Adam R Schertz, MD; Matt Strong, ADN, RN; Alexander O. Sy, MD; Braghadheeswar Thyagarajan MD; Amy Townsend, ACGNP; Russell Worthen, FNP-BC; Michael Wlodarski, PA-C; Charles Yarbrough, ADN, RN; Caroline York, PA-C Bradley Lloyd, RRT-ACCS Christopher Adler, PA-C; Ahmed Agameya, MD; Michael Colancecco, DO; Daniel Fitelson, MD; Joshua Giaccotto, MD; Gena Han, DO; Louise Kane, MD; Ezra Miller, MD; Timothy Noland, PA-C; Jaqueline Price, PA-C; Joseph Plourde, PA-C; Emily Adams, PA-C; Fraser Mackay, MD; Laura Mahoney, PA-C; Avignat Patel, MD; Michael Plourde, PA-C; Zena Saadeh, PA-C; Sara Shadchehr, DO; Sandeep Somalaraju, MD; Eleanor Summerhill, MD; Ryan Webster, MD; Jordan Winnicki, PA-C; Ekaterina Yavarovich, DO Anna Altz-Stamm RN, BSN, CCRN; Cristina Bardita, MD, PhD; Mary Clay Boone RN, BSN; Joe W. Chiles III, MD; Kristina Collins RN, BSN; Abby Drescher RN, BSN; Kevin G. Dsouza, MD; Janna Dunn, RN, AND; Stacy Ejem, MD; Josh Gautney, MD; Nicole Harris, RN, ADN; Savannah Herder, RN, BSN; Tamer Hudali, MD, MPH; R. Chad Wade, MD; Rutwij Joshi, MBBS; Daniel Kelmenson, MD; Anne Merrill Mason RN, BSN; Scott R. Merriman, MD; Takudzwa Mkorombindo, MD; Megan Moore, RN, MSN; Jada Nowak, RN, BSN; Kate O'Connor, DO; David B. Page, MD; Sheylan D. Patel, MD; G. Bruno Pereira, MD, PhD; Lisa Sarratt RN, BSN; Tabitha Stewart RN, BSN; William S. Stigler, MD; Kadambari Vijaykumar, MBBS; Gina White RN, BSN; Micah R. Whitson, MD; Katherine O. Heller, MD; C. Cole Malibiran, BS; Milad K. Jouzestani; Chandani Anandkat Zachary Zouyed, BS; Matthew G. Drake, MD; Makrina N. Kamel, BS

